4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

BTIG Research initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $44.00

Wolfe Research initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $20.00

Stifel initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $49.00

H.C. Wainwright initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

Leerink Partners initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $44.00

TD Cowen initiated coverage of Oruka Therapeutics with a rating of Buy

Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $40.00

424B3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)

8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)

DEFA14A - Oruka Therapeutics, Inc. (0000907654) (Filer)

DEF 14A - Oruka Therapeutics, Inc. (0000907654) (Filer)

EFFECT - Oruka Therapeutics, Inc. (0000907654) (Filer)

POS AM - Oruka Therapeutics, Inc. (0000907654) (Filer)

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported second quarter 2025 financial results and provided a corporate update. "We are very pleased to have initiated our EVERLAST-A study, and we expect nearl

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV in September MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the U.S. FDA cleared its investigational new drug (IND) application for its Phase 2a trial of ORKA-001 (the Company's long-acting anti-IL-23p19 antibody) in moderate-

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operations, development strategy, and quality. She has played a pivotal role in progressing Oruka's programs from preclinical stages into clinical trials with speed and precision. "I've had the privilege

MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY: Date: Wednesday, June 4th, 2025Time: 12:50PM ET A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatme

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-002, the Company's novel, subcutaneously administere

Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, Phase 1 initiation accelerated to 2Q 2025, with initial PK data now expected around YE 2025; data will support both ORKA-002 and ORKA-021 psoriasis studies Strong cash position of $373 million provides runway through 2027, over one year past anticipated ORKA-001 Phase 2a data in psoriasis MENLO PARK, Calif., May

MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at 3:55 PM PT. About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their c

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, preclinical data to be presented at the 2025 AAD Annual Meeting; Phase 1 initiation expected in Q3 2025, with PK data in 1H 2026 Successful go-public transaction and over $475 million raised in 2024 $394 million of cash, cash equivalents, and marketable securities at year-end 2024, projected to fund company through 2027, over one year past anticipated ORKA-001 Phase 2a data in psoriasis MENLO

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: TD Cowen's 45th Annual Health Care ConferenceDate: Tuesday, March 4th, 2025Time: 10:30AM ET Leerink Global Healthcare ConferenceDate: Wednesday, March 12th, 2025Time: 8:40AM ET A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About O

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026 Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healt

SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)